These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 15626356)

  • 1. [Rapamycin: from the laboratory to the treatment of patients' arteries].
    Fuster V
    Rev Esp Cardiol; 2003; 56 Suppl 1():2-6. PubMed ID: 15626356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug-eluting stents.
    García-García HM; Vaina S; Tsuchida K; Serruys PW
    Arch Cardiol Mex; 2006; 76(3):297-319. PubMed ID: 17091802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapamycin inhibits human in stent restenosis vascular smooth muscle cells independently of pRB phosphorylation and p53.
    Rosner D; McCarthy N; Bennett M
    Cardiovasc Res; 2005 Jun; 66(3):601-10. PubMed ID: 15914125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel site-specific systemic delivery of Rapamycin with perfluorobutane gas microbubble carrier reduced neointimal formation in a porcine coronary restenosis model.
    Kipshidze NN; Porter TR; Dangas G; Yazdi H; Tio F; Xie F; Hellinga D; Wolfram R; Seabron R; Waksman R; Abizaid A; Roubin G; Iyer S; Colombo A; Leon MB; Moses JW; Iversen P
    Catheter Cardiovasc Interv; 2005 Mar; 64(3):389-94. PubMed ID: 15736246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Everolimus, a promising medical therapy for coronary heart disease?
    Jia L; Hui RT
    Med Hypotheses; 2009 Aug; 73(2):153-5. PubMed ID: 19375241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized comparison of sirolimus-eluting stent versus standard stent for percutaneous coronary revascularization in diabetic patients: the diabetes and sirolimus-eluting stent (DIABETES) trial.
    Sabaté M; Jiménez-Quevedo P; Angiolillo DJ; Gómez-Hospital JA; Alfonso F; Hernández-Antolín R; Goicolea J; Bañuelos C; Escaned J; Moreno R; Fernández C; Fernández-Avilés F; Macaya C;
    Circulation; 2005 Oct; 112(14):2175-83. PubMed ID: 16203930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical and early clinical experience with a biodegradable polymer-based, rapamycin-eluting, Indian drug-eluting coronary stent: the BIO-RAPID study.
    Bhargava B; Karthikeyan G; Shankar PB; Seth S; Singh S; Pr U; Lal AV; Mohanty M
    Indian Heart J; 2008; 60(3):228-32. PubMed ID: 19240312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized trial of a nonpolymer-based rapamycin-eluting stent versus a polymer-based paclitaxel-eluting stent for the reduction of late lumen loss.
    Mehilli J; Kastrati A; Wessely R; Dibra A; Hausleiter J; Jaschke B; Dirschinger J; Schömig A;
    Circulation; 2006 Jan; 113(2):273-9. PubMed ID: 16391155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Are impaired endothelial progenitor cells involved in the processes of late in-stent thrombosis and re-endothelialization of drug-eluting stents?
    Zhao FH; Chen YD; Jin ZN; Lu SZ
    Med Hypotheses; 2008; 70(3):512-4. PubMed ID: 17764856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short- and long-term effects of cytochalasin D, paclitaxel and rapamycin on wall thickening in experimental porcine vein grafts.
    Murphy GJ; Johnson TW; Chamberlain MH; Rizvi SI; Wyatt M; George SJ; Angelini GD; Karsch KR; Oberhoff M; Newby AC
    Cardiovasc Res; 2007 Feb; 73(3):607-17. PubMed ID: 17187765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral rapamycin after coronary bare-metal stent implantation to prevent restenosis: the Prospective, Randomized Oral Rapamycin in Argentina (ORAR II) Study.
    Rodriguez AE; Granada JF; Rodriguez-Alemparte M; Vigo CF; Delgado J; Fernandez-Pereira C; Pocovi A; Rodriguez-Granillo AM; Schulz D; Raizner AE; Palacios I; O'Neill W; Kaluza GL; Stone G;
    J Am Coll Cardiol; 2006 Apr; 47(8):1522-9. PubMed ID: 16630986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term clinical benefit of sirolimus-eluting stent implantation in diabetic patients with de novo coronary stenoses: long-term results of the DIABETES trial.
    Jiménez-Quevedo P; Sabaté M; Angiolillo DJ; Alfonso F; Hernández-Antolín R; SanMartín M; Gómez-Hospital JA; Bañuelos C; Escaned J; Moreno R; Fernández C; Fernández-Avilés F; Macaya C;
    Eur Heart J; 2007 Aug; 28(16):1946-52. PubMed ID: 17562666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Rapamycine and mTOR inhibitors: from bench to bedside].
    Pallet N; Beaune P; Legendre C; Anglicheau D
    Ann Biol Clin (Paris); 2006; 64(2):107-15. PubMed ID: 16556521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapamycin treatment is associated with an increased apoptosis rate in experimental vein grafts.
    Schachner T; Oberhuber A; Zou Y; Tzankov A; Ott H; Laufer G; Bonatti J
    Eur J Cardiothorac Surg; 2005 Feb; 27(2):302-6. PubMed ID: 15691686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Coronary in-stent restenosis in diabetic patients after implantation of sirolimus or paclitaxel drug-eluting coronary stents.
    Kitoga M; Pasquet A; Preumont V; Kefer J; Hermans MP; Vanoverschelde JL; Buysschaert M
    Diabetes Metab; 2008 Feb; 34(1):62-7. PubMed ID: 18069029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of clinical and angiographic outcomes after Excel bioabsorbable polymer versus Firebird durable polymer rapamycin-eluting stent for the treatment of coronary artery disease in a "real world" setting: six-month follow-up results.
    Liu HB; Xu B; Qiao SB; Yang YJ; Ma WH; Qin XW; Yao M; Wu YJ; Yuan JQ; Chen J; You SJ; Dai J; Xia R; Li JJ; Chen JL; Gao RL
    Chin Med J (Engl); 2007 Apr; 120(7):574-7. PubMed ID: 17442205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Comparison of the effects of rapamycin-eluting stent implantation and coronary artery bypass grafting in treatment of patients with multi-vessel coronary disease].
    Han YL; Wang XZ; Jing QM; Wang SL; Ma YY; Wang HS; Luan B
    Zhonghua Yi Xue Za Zhi; 2005 Oct; 85(40):2826-9. PubMed ID: 16324339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Orally administered rapamycin does not modify rat aortic vascular tone.
    Neto Mde M; Di Marco GS; Casarini DE; Lima VC; Campos AH
    J Cardiovasc Pharmacol; 2007 Feb; 49(2):96-9. PubMed ID: 17312450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The present and future of drug-eluting stents.
    Indolfi C; Mongiardo A; Spaccarotella C; Ferraro A; Torella D
    Ital Heart J; 2005 Jun; 6(6):498-506. PubMed ID: 16008155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapamycin: an anti-cancer immunosuppressant?
    Law BK
    Crit Rev Oncol Hematol; 2005 Oct; 56(1):47-60. PubMed ID: 16039868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.